Last updated on July 2017

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)


Brief description of study

Leukotriene B4 (LTB4) inhibits lymphangiogenesis in the mouse tail model of lymphedema and is elevated in tissue in patients with lymphedema. Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4. This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema. The primary objectives for the study are: - To evaluate the efficacy of ubenimex in patients with leg lymphedema - To evaluate the safety and tolerability of ubenimex in patients with leg lymphedema

Clinical Study Identifier: NCT02700529

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Leslie Jacome-Roche

Stanford University
Stanford, CA United States
  Connect »

Jennifer Quintiliani

Orlando Health, Inc.
Orlando, FL United States
  Connect »

Filiz Muharrem

The Ohio State University Wexner Medical Center James Cancer Hospital
Columbus, OH United States
  Connect »

Louise Koelmeyer

Macquarie University Hospital (MUH)
Macquarie University, Australia
  Connect »